Iridex to Report First Quarter 2021 Financial Results on May 11, 2021

Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) announced that it will release its financial results for Q1 2021 on May 11, 2021, after trading hours. A conference call will follow at 2:00 p.m. PT / 5:00 p.m. ET. The call can be accessed by domestic callers at (844) 707-0665 and international callers at (703) 326-3030, using conference ID: 1282162. Iridex specializes in innovative ophthalmic laser-based medical products for glaucoma and retinal diseases, utilizing its proprietary MicroPulse® technology to deliver effective treatments worldwide.

Positive

• Company is a leader in ophthalmic laser-based medical products.
• Proprietary MicroPulse® technology provides safe and effective treatments.
• Products sold in the U.S. and over 100 countries indicates a broad market presence.

Negative

• None.

MOUNTAIN VIEW, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of 2021 after the close of trading on Tuesday, May 11, 2021. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 1282162. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com.

About Iridex
Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse^® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.

Investor Relations Contact:
Leigh Salvo
(415) 937-5404
investors@iridex.com

Media Contact:
Jamie Hall
Pascale Communications, LLC.
(724) 417-0167
pr@iridex.com

 

FAQ

When will Iridex announce its Q1 2021 financial results?

Iridex will release its Q1 2021 financial results after trading on May 11, 2021.

What time is the Iridex conference call for Q1 2021 results?

The conference call will begin at 2:00 p.m. PT / 5:00 p.m. ET on May 11, 2021.

How can I listen to Iridex's Q1 2021 conference call?

Investors can listen to the call by dialing (844) 707-0665 for domestic calls or (703) 326-3030 for international calls, using conference ID: 1282162.

What is the focus of Iridex Corporation's products?

Iridex focuses on innovative ophthalmic laser-based medical products for treating glaucoma and retinal diseases.

In how many countries are Iridex products sold?

Iridex products are sold in the United States and over 100 countries.